Osteosarcoma (OS) has a high mortality rate and remains in need of more effective therapeutic approaches. Survivin is an IAP family member protein that blocks apoptosis and drives proliferation in human cancer cells where it is commonly elevated. In this study, we illustrate the superiority of a canine OS model as a translational tool for evaluating survivin-directed therapies, owing to the striking similarities in gross and microscopic appearance, biologic behavior, gene expression and signaling pathway alterations. Elevated survivin expression in primary canine OS tissue correlated with increased histologic grade and mitotic index and a decreased disease free interval (DFI). Survivin attenuation in canine OS cells inhibited cell cycle progression, increased apoptosis, mitotic arrest and chemosensitivity, and cooperated with chemotherapy to significantly improve in vivo tumor control. Our findings illustrate the utility of a canine system to more accurately model human OS and strongly suggest that survivin-directed therapies might be highly effective in its treatment.
INTRODUCTION

Osteosarcoma (OS) is the most common primary bone tumor in dogs and
humans (1) (2) (3) , and is characterized by both aggressive local tissue infiltration and a very high metastatic rate. Despite the use of neoadjuvant and adjuvant chemotherapy, the 5-year survival rate is only 60% in humans and the 2-year survival rate is only 20% in dogs, illustrating that new therapeutics are needed (1) .
The dog is a well-established model for spontaneous OS in humans, owing to striking similarity in biology and gene expression (3, 4) . The dog's large size, relative outbreeding and immunocompetence increase their model potential. Furthermore, dogs with spontaneous tumors naturally develop therapy resistance and metastasis.
Additionally, tumor burdens in spontaneously arising cancers of dogs are more similar to humans than the experimentally-induced tumors found in murine models, which may be important with regard to biologic factors such as hypoxia and clonal variation. The size of canine tumors also allows for serial imaging and tissue collection over time (3, 4) .
Survivin is a 16.5 kD protein belonging to the Inhibitor of Apoptosis (IAP) family (5) . The survivin gene has five known mRNA splice variants: Survivin, Survivin-2B, Survivin-ΔEx3, Survivin-3B, and Survivin-2α (6) . Unlike other IAP family members, survivin has two known functions in cells: regulation of cell division and inhibition of apoptosis (7) . Survivin is found as a monomer in the chromosomal passenger complex (CPC) and binds via its C terminal to the microtubules of the mitotic spindle during mitosis (8) . Survivin is dimeric in its role as an IAP molecule (9) and is thought to have targets upstream of effector caspases or target effector caspases themselves (10, 11) .
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Author Manuscript Published OnlineFirst on November 8, 2011; DOI: 10.1158/0008-5472. CAN-11-2315 Evidence suggests that survivin plays a role in inhibiting both caspase-dependent and caspase-independent apoptosis (12, 13) . Survivin may also indirectly inhibit apoptosis, via binding to the proapoptotic protein Smac/DIABLO, preventing it from binding to and inhibiting other IAP molecules (14). Some survivin is localized to the mitochondria and is thought to prevent apoptosis upon release as well as block the release of apoptosisinducing factor (AIF) (13) . Both cytoplasmic and mitochondrial survivin are thought to inhibit apoptosis via binding to other proteins, possibly the effector caspases or other associated proteins (10, 15) .
More recent evidence suggests that survivin also enhances telomerase activity, and may play a role in chemotherapy resistance and metastasis (16) (17) (18) (19) .
Normal cells do not require survivin for survival (20) . In cancer cells, however, survivin is critical for its roles in cell division and inhibition of apoptosis (5) . It also appears to have roles in tumorigenesis (15, 21) and drug resistance (17, 18) .
Hematopoietic progenitor cells, thymocytes, and T-cells express survivin at low levels for cell proliferation (22) (23) (24) ; however, differentiated cells do not express survivin. More specific to the purpose of our study, survivin is only expressed at very low levels in normal osteoblasts (25) . Most types of cancer express survivin at very high levels and depend on it for continued proliferation (5, 20) .
Survivin expression has prognostic significance in many types of human cancer (26) . Small studies in human OS have suggested that survivin may be useful in determining prognosis and degree of malignancy (27) (28) (29) ; however, definitive studies regarding the role of survivin in human OS are lacking. Survivin expression is a negative prognostic factor in dogs with B-cell lymphoma (30) , as has been
Research. CAN-11-2315 demonstrated in human B-cell lymphoma (31) , and survivin expression has been identified in select other canine neoplasms (30) .
In this study, we sought to determine the effects of survivin inhibition in canine OS cell lines and to evaluate a correlation between survivin expression and outcome in canine OS patients. We hypothesized, as observed in human OS, that survivin inhibition would decrease cell proliferation and increase apoptosis and chemosensitivity in canine OS cells, and that increased survivin expression would correlate with a poor prognosis in canine OS patients.
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MATERIALS AND METHODS
Cell lines and conditions
The Abrams canine OS cell line was provided by Dr. William Dernell, and the D17 canine OS cell line was purchased from American Type Culture Collection 
siRNA Transfection
A custom siRNA against canine survivin (430) and a scrambled siRNA control were designed using an online resource (BLOCK-iT TM RNA Designer, Invitrogen, Detailed methods for the techniques described below are included in the Supplemental Data.
qRT-PCR -We evaluated survivin mRNA in the survivin siRNA transfected, sham transfected and control cells at 48 hours post transfection using real-time RT-PCR. Primers for canine survivin and the housekeeping gene, HPRT, were designed using Integrated DNA Technologies' (IDT) website and purchased from IDT (Coralville, IA) ( Table S1 ).
Immunofluorescence -Transfected cells were washed, fixed methanol and air- Western blot -At 48 hours post transfection, the cells were harvested, protein quantified and equal amounts loaded onto a 4-12% Bis-Tris gel (Invitrogen), followed by electrophoresis and transfer to a polyvinylidene difluoride (PVDF) membrane. The membrane was then blocked in 5% non-fat dry milk in TBST, followed by incubation with rabbit polyclonal anti-survivin (Novus) followed by HRP conjugated goat anti-rabbit IgG (Pierce, Rockford, IL). Protein bands were detected using SuperSignal West
Femto Maximum Sensitivity ECL Substrate (Thermo Scientific) using radiographic film (Kodak, Rochester, New York). The images were scanned and pixel density assessed using Image J (NIH).
Cell Number and Viability
To determine cell numbers, total and live/dead cell numbers were counted in triplicate at 24, 48, 72 hours post transfection using trypan blue.
Apoptosis
Caspase-3/7 Assay -To determine levels of apoptosis, we used a SensoLyte 
Murine Xenograft Experiment
Female 6-8 week old nu/nu mice were purchased from the National Institutes of Health. EZN-3042, a survivin inhibiting locked nucleic acid antisense oligonucleotide (33, 34) , and EZN-3046 (scrambled control oligonucleotide) were supplied by Enzon Pharmaceuticals (Piscataway, NJ). After demonstration of gene knockdown efficacy in vitro (not shown), mice were injected subcutaneously with 2x10 6 Abrams OS cells.
Tumors were grown to 7 mm diameter, size-matched and then allocated into 4 groups (n=8 per group). Group 1 received saline and EZN-3046, group 2 received DOX (Bedford) and EZN-3046, group 3 received saline and EZN-3042, and group 4 received DOX and EZN-3042. EZN-3042 and EZN-3046 were administered intraperitoneally at 100 mg/kg every three days starting day 0 until the end of the study (day 55).
Doxorubicin or an equivalent volume of saline was administered intravenously at 3
Research. mg/kg on day 4 and repeated every two weeks until the end of the study. Mice were weighed and tumors measured every three days. Mice were sacrificed at 15 mm tumor diameter or at the end of the study if they were still alive. A separate group of tumorbearing mice were randomized similarly at 10 mm tumor diameter. They received EZN-3042 or EZN-3046 on days 0 and 3 (AM) and DOX or saline on day 3 (PM) and sacrificed on day 4. Tumors were harvested and snap-frozen or paraffin embedded for analysis of survivin expression by qRT-PCR as described above and immunohistochemistry as described below.
Canine Osteosarcoma Patient Population
The population of canine appendicular OS patients studied was a subset of patients from a previously reported randomized, prospective clinical trial (35) . The study was approved by the Institutional Animal Care and Use Committees of the participating institutions. All dogs underwent amputation followed by 5 cycles of adjuvant DOX, with or without an investigational matrix metalloprotease inhibitor and had decalcified primary tumor tissue blocks available for analysis. Inclusion/exclusion criteria, staging, and follow-up procedures were standardized as previously reported (35) . Histologic grading (from 1 to 3) was performed in a subset of cases by one author (BEP) utilizing a published schema incorporating amount of matrix, percent necrosis, nuclear pleomorphism, nucleolar size/number and mitosis score (35) . Mitotic index was also calculated by counting the number of mitotic figures per 10 random 400X fields.
Survivin Immunohistochemistry
Statistical analysis
Statistical analysis of in vitro data was performed using GraphPad Prism for 
Macintosh Version 5.0b (GraphPad Software, La Jolla, CA). Survivin expression levels were summarized by standard descriptive statistics in terms of means and standard deviations. The comparisons of survivin expression, cell numbers, caspase activity and apoptosis levels between experimental conditions was performed using a two-sample ttest with a two-sided significance level. Tumor growth between groups was evaluated using a 1-way ANOVA. The Shapiro Wilk test was used to verify the normality assumption. P-values of less than 0.05 were considered statistically significant. Statistical analysis of survival data was performed using a combination of Prism and SAS software version 9.2 (SAS Institute, Cary, NC, USA). Correlations between survivin expression levels and other markers on a continuous scale were evaluated using linear regression analysis. Analysis of variance was used to evaluate the association between survivin expression levels and categorical markers. The median disease free interval (DFI) was estimated using the Kaplan-Meier method. Markers were categorized into a low risk and high risk group (with respect to predicting DFI) using the recursive portioning method (38) . This method selects the best predictor variables using recursive splitting. It starts with the best possible predictor from the data set and successively splits the data into categories predicted to observe the event or not. As a splitting method, the exponential scaling method was used. The splitting process stopped when a minimum of five patients per groups was reached or when 
there was no further decrease in prediction error. The associations between the categorized markers and DFI were evaluated using the log-rank test. Multivariate Cox proportional hazard regression analysis was used to determine the prognostic significance of the markers for predictive value of DFI. Predictive markers were selected by backward selection procedures with a p-value cut off of <0.10. A previously deleted variable was allowed to re-enter the final model if its p-value was <0.05. The likelihood ratio test was used to compare various models. The proportional hazard assumption was verified using plots of the log(-log) survival curves and Schoenfeld residuals. (Fig. 1a) .
Since inhibition of survivin mRNA expression does not confirm decreased survivin protein, we performed further experiments to verify decreased protein expression. Western blot analysis of Abrams and D17 cells confirmed approximately 85% reduction in protein expression in survivin siRNA transfected groups compared to the sham transfected and control groups (Fig. 1b, 1c) .
Immunofluorescence cytochemistry further confirmed reduced survivin protein expression. Based on immunofluorescence assessment, knockdown efficacy was 80.2 +/-7.1% for Abrams and 76.2 +/-9.4% for D17 (Fig. S1) .
Survivin inhibition decreases total cell number and cell viability. Total and
live/dead cell counts were performed at 24, 48, and 72 hours post survivin knockdown in both cell lines. At all three time points, there were significantly decreased total cell numbers and significantly higher percent dead cells in the survivin siRNA transfected cells compared to both the sham transfected and control groups (Fig. S2) .
Research. Survivin inhibition increases apoptosis. To determine if the cell death observed was via apoptosis, we evaluated caspase-3,7 activity in the survivin siRNA transfected, sham transfected, and control cells 48 hours post transfection. There was a significant increase in caspase activity in survivin siRNA transfected cells compared to their respective sham transfected and control cells (Fig. 2a) . This was confirmed by observation of increased DNA fragmentation 48 hours post siRNA transfection, as assessed via TUNEL (Fig. 2b) . respectively, and the super-G2 (4N) population increased an average of 3.5 and 2.5-fold in Abrams (Fig. 3a,b) and D17 (Fig. 3c) respectively.
Survivin inhibition results in
Survivin inhibition increases chemosensitivity. Doxorubicin and platinum drugs
form the mainstays of medical therapy for the treatment of both canine and human OS.
To determine if survivin was important in mediating resistance to chemotherapy in canine OS, we incubated canine OS cells with CPT or DOX, with or without concurrent survivin or sham siRNA transfection. Survivin knockdown increased caspase activity in both cell lines in the presence of DOX and CPT (Fig. 4) .
Survivin inhibition in canine OS xenografts results in increased doxorubicin
sensitivity. Survivin knockdown in vivo was accomplished using the locked nucleic acid (Fig. 5a) .
Notably there was a significant increase in survivin expression in the DOX/EZN-3046 group compared to the control (saline/EZN-3046) (Fig. 5a) , suggesting possible survivin induction as a DOX response mechanism. Tumor growth rate was significantly reduced in the combined EZN-3042/DOX treated group compared to the other treatment groups (Fig. 5b) .
Survivin protein expression in canine OS tissues correlates with histologic features and clinical outcome.
Survivin expression was studied via immunohistochemistry in 67 primary canine OS tissues from dogs that underwent Table S2 . Survivin was expressed in 65 of 67 cases evaluated, with expression intensity ranging from modest to heavy (Fig. S3) .
Median survivin immunoreactivity score was 5 (range, 0 to 12). Staining was predominantly nuclear, although a combination of nuclear and cytoplasmic staining was observed in most samples. Survivin immunoreactivity score correlated positively with both histologic grade and mitotic index (Figs. 6a and b) .
The overall median DFI in the studied patient population was 211 days (range 43
Research. CAN-11-2315 -1,393+ days). Upon univariate analysis, histologic grade (1/2 vs. 3), bone-specific alkaline phosphatase (BALP) activity ( 48 vs. >48) and survivin immunoreactivity score ( 2.75 vs. >2.75) were identified as significant predictors of DFI (Table 1, Fig. 6c ). The median DFI in patients with a lower survivin immunoreactivity score ( 2.75) was 331 days versus 173 days in patients with a higher survivin immunoreactivity score (>2.75) (p = 0.046).
As observed in the original clinical trial (35), drug assignment did not impact DFI.
Upon multivariate analysis, BALP and histologic grade retained prognostic significance ( Table 1) . Survivin immunoreactivity was not identified as an independent significant predictor of DFI in the multivariate analysis, owing in large part to the strong positive correlation between survivin immunoreactivity and histologic grade. This observed increase in 4N(+) population could be attributed to the importance of survivin in the chromosomal passenger complex (8) and its association to the mitotic spindle during mitosis (7, 20) . Additionally, siRNA-mediated survivin inhibition in human MG-63 OS cells and shRNA-mediated survivin inhibition of human SAOS2 OS cells enhanced sensitivity to cisplatin and DOX (41, 42) .
DISCUSSION
We observed significantly increased apoptosis in survivin knockdown compared to the sham knockdown and control cells in both canine OS cell lines in the absence of any pro-apoptotic stimulus (e.g. serum withdrawal or chemotherapy). There was also modestly increased apoptosis in the sham knockdown compared to the control for both There was a significant correlation between survivin immunoreactivity and mitotic index in primary canine osteosarcomas. C. Canine osteosarcoma patients treated with amputation and doxorubicin with high survivin immunoreactivity scores had a significantly inferior disease-free interval on univariate analysis.
